DALY 2-EURecruiting

DALY-2

Gender
Women and men
Age
18–70 years
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase
Phase II

What is this trial about?

The DALY-2 study aims to investigate whether, in patients with a relapse of an aggressive form of lymphoma (known as DLBCL), the body’s own modified immune cells (known as CAR-T cells) are more effective than chemotherapy.

Detailed description

CAR-T cells are the body's own immune cells that are genetically modified in the laboratory to specifically target and kill tumor cells. This therapy has been developed over the past 10 years and has already yielded very good results in treating a number of types of lymphoma.

Trial sites

16 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Augsburg

    Stenglinstrasse 2, 86156 Augsburg

    Recruiting

  • Helios Klinikum Berlin-Buch GmbH

    Schwanebecker Chaussee 50, 13125 Berlin

    Status unknown

  • Universitaetsklinikum Knappschaftskrankenhaus Bochum der Ruhr-Universitat Bochum

    44892 Bochum

    Recruiting

  • Universitätsklinikum Knappschaftskrankenhaus Bochum

    In Der Schornau 23-25, 44892 Bochum

    Status unknown

  • Universitätsklinikum Carl Gustav Carus Dresden

    Fetscherstraße 74, 01307 Dresden

    Active, not recruiting

  • Universitätsklinikum Erlangen

    91054 Erlangen

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT04844866) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.